Index Entries

Manuela De Michele, Giulia d’Amati, Martina Leopizzi, Marta Iacobucci, Irene Berto, Svetlana Lorenzano, Laura Mazzuti, Ombretta Turriziani, Oscar G. Schiavo, and Danilo Toni
August 16, 2022
Journal of Hematology & Oncology
Sapienza University of Rome (Italy)

Abstract: The pathophysiology of COVID-19-associated coagulopathy is complex and not fully understood. SARS-CoV-2 spike protein (SP) may activate platelets and interact with fibrin(ogen). We aimed to investigate whether isolated SP can be present in clots retrieved in COVID-19 patients with acute ischemic stroke (by mechanical thrombectomy) and myocardial infarction. In this pilot study, we could detect SP, but not nucleocapsid protein, on platelets of COVID-19 patients’ thrombi. In addition, in all three COVID-19 thrombi analyzed for molecular biology, no SARS-CoV-2 RNA could be detected by real-time polymerase chain reaction. These data could support the hypothesis that free SP, besides the whole virus, may be the trigger of platelet activation and clot formation in COVID-19.

document
COVID-19,mRNA,SARS-CoV-2 spike protein,vaccine systemic and virological concerns,vaccines